MedTrace Logo

Dexamethasone Versus Nalbuphine as Adjuvants in Brachial Plexus Block

NCT04194320 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-10-01

No results posted yet for this study

Summary

Brachial plexus block is a very reliable method of regional anesthesia for the upper limb. It achieves ideal operating conditions by producing complete muscular relaxation and stable intraoperative hemodynamics.However,Local anesthetics alone have a shorter duration of postoperative analgesia. Hence,various adjuvants have been added to local anesthetics to achieve quick, dense, and prolonged block. This study assess and compare the efficacy of dexamethasone or nalbuphine as adjuvants to local anesthetics in supraclavicular brachial plexus block for upper limb surgeries.

Conditions

  • Anesthesia

Interventions

PROCEDURE

Ultrasound (US) guided supraclavicular brachial plexus block

Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Mohamed ELSayed, MSc · Faculty of medicine, zagazig university, Egypt

  • Ahmed mohamed Salama, MD · Faculty of medicine, zagazig university, Egypt

  • Ayman Abd-El Salam Hassan, MD · Faculty of medicine, zagazig university, Egypt

  • Fatma Mahmoud Ahmed, MD · Faculty of medicine, zagazig university, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2020-05-05
Completion
2020-06-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04194320 on ClinicalTrials.gov